Biohaven Pharmaceutical Holding Total Liabilities 2016-2022 | BHVN

Biohaven Pharmaceutical Holding total liabilities from 2016 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Biohaven Pharmaceutical Holding total liabilities for the quarter ending March 31, 2022 were $1.838B, a 43.46% increase year-over-year.
  • Biohaven Pharmaceutical Holding total liabilities for 2021 were $1.82B, a 68.67% increase from 2020.
  • Biohaven Pharmaceutical Holding total liabilities for 2020 were $1.079B, a 206.85% increase from 2019.
  • Biohaven Pharmaceutical Holding total liabilities for 2019 were $0.352B, a 152.85% increase from 2018.
Biohaven Pharmaceutical Holding Annual Total Liabilities
(Millions of US $)
2021 $1,820
2020 $1,079
2019 $352
2018 $139
2017 $15
2016 $29
2015 $1
Biohaven Pharmaceutical Holding Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $1,838
2021-12-31 $1,820
2021-09-30 $1,722
2021-06-30 $1,302
2021-03-31 $1,281
2020-12-31 $1,079
2020-09-30 $996
2020-06-30 $460
2020-03-31 $411
2019-12-31 $352
2019-09-30 $320
2019-06-30 $304
2019-03-31 $148
2018-12-31 $139
2018-09-30 $129
2018-06-30 $120
2018-03-31 $18
2017-12-31 $15
2017-09-30 $28
2017-06-30 $21
2017-03-31 $40
2016-12-31 $29
2016-09-30 $0
2016-06-30 $0
2016-03-31
2015-12-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.248B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00